Evidence map›Paper›PMID 30100989›Full record

ArticleOncotarget2018

The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab.

Matthias F Froelich, Sebastian Stintzing, Jörg Kumbrink, Thomas G P Grünewald, Ulrich Mansmann, Volker Heinemann, Thomas Kirchner, Andreas Jung

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Matthias F FroelichInstitute of Pathology, Medical Faculty, LMU Munich, Munich, Germany.
Sebastian StintzingDepartment of Medicine III, University Hospital LMU Munich, Munich, Germany.
Jörg KumbrinkInstitute of Pathology, Medical Faculty, LMU Munich, Munich, Germany.
Thomas G P GrünewaldInstitute of Pathology, Medical Faculty, LMU Munich, Munich, Germany.
Ulrich MansmannGerman Cancer Research Centre (DKFZ); German Cancer consortium (DKTK), Heidelberg, Germany.
Volker HeinemannDepartment of Medicine III, University Hospital LMU Munich, Munich, Germany.
Thomas KirchnerInstitute of Pathology, Medical Faculty, LMU Munich, Munich, Germany.
Andreas JungInstitute of Pathology, Medical Faculty, LMU Munich, Munich, Germany.
Deutschen Konsortium für Translationale Krebsforschung · DELMU Klinikum · DEGerman Cancer Research Center · DEZimmer Biomet (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skin toxicity (ST) is a frequent adverse effect (AE) in anti-epidermal growth factor receptor (EGFR)-targeted treatment of metastatic colorectal cancer (mCRC) resulting in decreased quality of life and problems in clinical management. We wanted to identify biomarkers predicting ST in this setting and focused on 70 DNA polymorphisms associated with acne, the (immunoglobulin fragment crystallizable region) Fcγ-receptor pathway, and systemic lupus erythematosus (SLE) applying next-generation-sequencing (NGS). For the analysis patients with mCRC treated with cetuximab were selected from the FIRE-3 study. A training group consisting of the phenotypes low (1) - and high-grade (3) ST (

Indexed as

colorectal cancerskin toxicitySNPs

Identifiers

PMID30100989
PMCPMC6084390
OpenAlexW2884065950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.